--- title: "A Look At Capricor Therapeutics’ (CAPR) Valuation After FDA Resumes Deramiocel Review On New HOPE-3 Data" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/279151959.md" description: "Capricor Therapeutics (CAPR) is in the spotlight as the FDA resumes its review of Deramiocel, backed by new HOPE-3 Phase 3 data. Despite a recent share price drop of 8.74% to $30.50, the stock has seen a 35.86% return over the past month and a 130.54% return over the past year. Analysts suggest the stock is undervalued, with a fair value estimate of $50.80, while concerns about potential FDA delays and rising costs remain. The SWS DCF model indicates a future cash flow value of $312.65, but traditional metrics show a high P/B ratio of 20.9x." datetime: "2026-03-15T10:35:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279151959.md) - [en](https://longbridge.com/en/news/279151959.md) - [zh-HK](https://longbridge.com/zh-HK/news/279151959.md) --- > 支持的语言: [English](https://longbridge.com/en/news/279151959.md) | [繁體中文](https://longbridge.com/zh-HK/news/279151959.md) # A Look At Capricor Therapeutics’ (CAPR) Valuation After FDA Resumes Deramiocel Review On New HOPE-3 Data Capricor Therapeutics (CAPR) is back in focus after the FDA resumed review of its Biologics License Application for Deramiocel, supported by new HOPE-3 Phase 3 data in Duchenne muscular dystrophy cardiomyopathy. See our latest analysis for Capricor Therapeutics. The FDA decision and fresh HOPE-3 data arrived after a strong run, with a 30 day share price return of 35.86% and a one year total shareholder return of 130.54%. This comes even though the stock has pulled back 8.74% on the day to US$30.50, as investors weigh the wider full year loss. If Capricor’s story has you looking at what is next in healthcare, you might also want to scan our screener of 33 healthcare AI stocks as another way to spot potential opportunities in the sector. With shares up triple digits over the past year and trading at a reported 90% discount to one intrinsic value estimate, investors now face a simple question: Is Capricor undervalued, or is the market already pricing in future growth? ## Most Popular Narrative: 40% Undervalued Capricor Therapeutics last closed at $30.50, while the most followed narrative pegs fair value at $50.80. This creates a wide gap that hinges on future execution. > _Advancements in regulatory pathways for rare diseases and cell therapies, along with Capricor's demonstrated manufacturing readiness and quality approvals, set the stage for accelerated approval and commercialization. This may shorten the path to revenue generation and potentially expand gross margins earlier than currently reflected in the stock._ _Read the complete narrative._ Curious what turns that regulatory and manufacturing setup into a much higher fair value? The narrative leans heavily on rapid revenue expansion, rising margins, and a future earnings multiple that assumes real momentum. The full story joins these moving parts into one valuation playbook. **Result: Fair Value of $50.80 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, the story can change quickly if Deramiocel faces further FDA delays, or if rising R&D and operating costs force additional equity raises and dilution. Find out about the key risks to this Capricor Therapeutics narrative. ## Another View: Rich On Traditional Metrics The SWS DCF model presents Capricor as deeply undervalued. The current $30.50 price sits well below an estimated future cash flow value of $312.65. Yet on a simple P/B ratio of 20.9x versus a 2.6x industry average, the stock appears expensive. Is this a rare opportunity, or is the DCF simply too optimistic? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:CAPR P/B Ratio as at Mar 2026 ## Next Steps With such mixed sentiment around Capricor, it makes sense to look at the numbers yourself and decide quickly where you stand based on the 3 key rewards and 3 important warning signs. ## Ready for more investment ideas? If you stop with just one stock, you risk missing other compelling setups that fit your style, so put the Simply Wall Street screener to work for you. - Target potential mispricing by scanning our list of 48 high quality undervalued stocks that combine attractive valuations with solid underlying fundamentals. - Secure your income focus by reviewing 14 dividend fortresses, a set of companies offering higher yields that might suit a dividend focused portfolio. - Prioritize resilience by checking 68 resilient stocks with low risk scores, where you can filter for businesses that score lower on risk indicators. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### 相关股票 - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [Capricor Therap (CAPR.US)](https://longbridge.com/zh-CN/quote/CAPR.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-CN/quote/LABU.US.md) ## 相关资讯与研究 - [Vertex Pharmaceuticals Inc - FDA expands indication for trikafta in cf patients ages 2 and older](https://longbridge.com/zh-CN/news/281371049.md) - [Regeneron Gets FDA OK for Extended Eylea HD Dosing](https://longbridge.com/zh-CN/news/281556416.md) - [Vertex Pharmaceuticals Says US FDA Approves Label Expansion for Alyftrek, Trikafta](https://longbridge.com/zh-CN/news/281365753.md) - [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/zh-CN/news/281346305.md) - [FDA Approves Dosing Interval Extension Up To 20 Weeks For EYLEA HD In WAMD And DME](https://longbridge.com/zh-CN/news/281744271.md)